ICER Releases Evidence Report on Multiple Myeloma Therapies

ICER has released a new evidence report on CAR T-cell therapies to treat multiple myeloma. All three therapeutics (idecabtagene vicleucel, ciltacabtagene autoleucel, and belantamab mafodotin-blmf) target the BCMA (B-cell maturation antigen) in pre-treated patients who have not been successful with other multiple myeloma therapies. The evidence report will be reviewed in a mid-April public meeting.

According to ICER President Dr. Steven Pearson, “Many people with multiple myeloma develop resistance to existing treatments, so these three new therapies that target BCMA — a new method of action — represent an important expansion of the clinical armamentarium available to patients and oncologists,” adding, “Data are extremely limited for the two CAR-Ts, but those data suggest the potential for patients to live longer with manageable side effects. At our public meeting, our policy roundtable will likely discuss the potential for certain patients to require a second dose of these CAR-Ts, and what the implications will be not only for how T-cells should be initially harvested, but also on the treatments’ overall pricing, coverage, and long-term value.” Read more here.

(Source: ICER, 4/5/21)